CSIMarket



Best Performing Stocks In Major Pharmaceutical Preparations Industry 2024 Year To Date



 1 Day   Week  Current Month of June  30 Days 
Current Quarter Q2 of 2024  90 Days    Ytd    12 Months 
 

Shares improved by 4.94% on average, in Major Pharmaceutical Preparations Industry 2024 year to date.

Here are the best performing stocks in Major Pharmaceutical Preparations Industry.




TCRT

$0.92

$0.8350 982.35%
2024 Year to Date


TCRT

$0.92

$0.8350 982.35%



Alaunos Therapeutics Inc

Alaunos Therapeutics Inc shares went up 982.35% 2024 year to date.


Alaunos Therapeutics Inc is a biotechnology company that operates on a research and development business model. Their focus is on discovering and developing innovative therapies for various diseases and medical conditions. Through their scientific expertise and collaborations, they aim to bring novel treatments to market to improve patient outcomes.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 220.842 mill. $ - mill. $ -36.456 mill. 240 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 220.842 mill.


$ - mill.


$ -36.456 mill.

Employees Shares Outstanding P/E

-


240 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



VCNX

$6.855

$6.1012 809.39%
2024 Year to Date


VCNX

$6.855

$6.1012 809.39%



Vaccinex Inc

Vaccinex Inc shares improved 809.39% 2024 year to date.


Vaccinex Inc operates on a biopharmaceutical business model, focusing on the development and commercialization of antibody-based therapies. The company utilizes its proprietary ActivMAb? Antibody Discovery Technology to discover and develop novel antibody therapeutics for the treatment of various diseases. Vaccinex collaborates with strategic partners and pharmaceutical companies to advance the clinical development and commercialization of its product candidates.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 30.894 mill. $ 0.795 mill. $ 2.765 mill. 5 mill. - Y/Y -60.00 %
Market Cap. Revenues TTM Net Income TTM

$ 30.894 mill.


$ 0.795 mill.


$ 2.765 mill.

Employees Shares Outstanding P/E

-


5 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -60.00 %


MRQ Y/Y - %



CRBP

$50.1

$43.7700 691.47%
2024 Year to Date


CRBP

$50.1

$43.7700 691.47%



Corbus Pharmaceuticals Holdings Inc

Corbus Pharmaceuticals Holdings Inc stock went up 691.47% 2024 year to date.


Corbus Pharmaceuticals Holdings Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for inflammatory and fibrotic diseases. Their business model revolves around conducting research and clinical trials to identify potential drug candidates, obtaining regulatory approvals, and subsequently commercializing these drugs to generate revenue. They aim to address unmet medical needs by creating and marketing novel treatments for diseases such as systemic sclerosis, cystic fibrosis, and other inflammatory conditions.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 221.623 mill. $ - mill. $ -47.461 mill. 4 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 221.623 mill.


$ - mill.


$ -47.461 mill.

Employees Shares Outstanding P/E

57


4 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



PCSA

$1.75

$1.3963 394.77%
2024 Year to Date


PCSA

$1.75

$1.3963 394.77%



Processa Pharmaceuticals Inc

Processa Pharmaceuticals Inc shares went up 394.77% 2024 year to date.


Processa Pharmaceuticals Inc is a biopharmaceutical company that operates by developing and commercializing innovative drug candidates for various medical conditions. They focus on advancing treatments through clinical trials, obtaining regulatory approvals, and partnering with other healthcare organizations for distribution and marketing.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 4.316 mill. $ - mill. $ -7.827 mill. 2 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 4.316 mill.


$ - mill.


$ -7.827 mill.

Employees Shares Outstanding P/E

-


2 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



RNA

$39.64

$30.4800 332.75%
2024 Year to Date


RNA

$39.64

$30.4800 332.75%



Avidity Biosciences Inc

Avidity Biosciences Inc stock went up 332.75% 2024 year to date.


Avidity Biosciences Inc*s business model revolves around developing and commercializing potential therapeutics using its proprietary AOC platform, which enables the targeted delivery of drugs to specific cells in the body.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 3,457.084 mill. $ 10.870 mill. $ -228.681 mill. 87 mill. - Y/Y 58.67 %
Market Cap. Revenues TTM Net Income TTM

$ 3,457.084 mill.


$ 10.870 mill.


$ -228.681 mill.

Employees Shares Outstanding P/E

-


87 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 58.67 %


MRQ Y/Y - %



RZLT

$3.95

$2.9350 289.16%
2024 Year to Date


RZLT

$3.95

$2.9350 289.16%



Rezolute Inc

Rezolute Inc shares improved 289.16% 2024 year to date.


Rezolute Inc*s business model involves developing and commercializing innovative therapies, focusing on rare and severe chronic metabolic and orphan diseases.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 200.703 mill. $ - mill. $ -58.211 mill. 51 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 200.703 mill.


$ - mill.


$ -58.211 mill.

Employees Shares Outstanding P/E

-


51 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



JAN

$2.36

$1.7528 288.67%
2024 Year to Date


JAN

$2.36

$1.7528 288.67%



Janone Inc

Janone Inc shares increased 288.67% 2024 year to date.


Janone Inc*s business model focuses on the design, manufacture, and sale of comfortable and stylish clothing for individuals with medical conditions, primarily sleep apnea.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 14.888 mill. $ - mill. $ -20.041 mill. 6 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 14.888 mill.


$ - mill.


$ -20.041 mill.

Employees Shares Outstanding P/E

-


6 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



JANX

$42

$30.9800 281.13%
2024 Year to Date


JANX

$42

$30.9800 281.13%



Janux Therapeutics Inc

Janux Therapeutics Inc shares went up 281.13% 2024 year to date.


Janux Therapeutics Inc is a biotechnology company that focuses on developing and commercializing innovative cancer treatments. Their business model revolves around leveraging their expertise in immunotherapies and bispecific antibody platforms to create novel therapies that target tumor cells and activate the patient*s immune system. By partnering with pharmaceutical companies and conducting clinical trials, they aim to bring effective and personalized cancer treatments to market.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 1,919.763 mill. $ 8.467 mill. $ -62.600 mill. 46 mill. - Y/Y 38.83 %
Market Cap. Revenues TTM Net Income TTM

$ 1,919.763 mill.


$ 8.467 mill.


$ -62.600 mill.

Employees Shares Outstanding P/E

-


46 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 38.83 %


MRQ Y/Y - %



MAIA

$3.95

$2.7600 231.93%
2024 Year to Date


MAIA

$3.95

$2.7600 231.93%



Maia Biotechnology Inc

Maia Biotechnology Inc shares went up 231.93% 2024 year to date.


Maia Biotechnology Inc is a biotechnology company that focuses on developing innovative therapies for cancer treatment. Their business model revolves around leveraging advanced genomic technologies to identify novel targets for drug development. By combining their expertise in genomics and drug discovery, they aim to create personalized and targeted therapies to improve patient outcomes in the field of oncology.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 54.019 mill. $ - mill. $ -5.307 mill. 14 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 54.019 mill.


$ - mill.


$ -5.307 mill.

Employees Shares Outstanding P/E

-


14 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



LPCN

$9.49

$6.6299 231.81%
2024 Year to Date


LPCN

$9.49

$6.6299 231.81%



Lipocine Inc

Lipocine Inc shares improved 231.81% 2024 year to date.


Lipocine Inc is a pharmaceutical company focused on developing oral drug delivery systems for hormone therapeutics. Their business model involves conducting research and development to create innovative products that address unmet medical needs in areas such as testosterone replacement therapy and hypogonadism. The company aims to commercialize these proprietary drug candidates and collaborate with industry partners to enhance their potential reach and impact.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 49.679 mill. $ -2.851 mill. $ -16.352 mill. 5 mill. - Y/Y 164.58 %
Market Cap. Revenues TTM Net Income TTM

$ 49.679 mill.


$ -2.851 mill.


$ -16.352 mill.

Employees Shares Outstanding P/E

-


5 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 164.58 %


MRQ Y/Y - %



GOVX

$1.2

$0.8300 224.32%
2024 Year to Date


GOVX

$1.2

$0.8300 224.32%



Geovax Labs Inc

Geovax Labs Inc stock increased 224.32% 2024 year to date.


Geovax Labs Inc*s business model primarily focuses on the development and commercialization of innovative vaccines to prevent and treat diseases, with a particular emphasis on HIV/AIDS. They aim to bridge the gap in preventing and managing these diseases through their vaccine candidates and strategic partnerships.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 2.840 mill. $ - mill. $ -24.224 mill. 2 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 2.840 mill.


$ - mill.


$ -24.224 mill.

Employees Shares Outstanding P/E

-


2 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



SMMT

$8.39

$5.7500 217.80%
2024 Year to Date


SMMT

$8.39

$5.7500 217.80%



Summit Therapeutics Inc

Summit Therapeutics Inc shares increased 217.80% 2024 year to date.


Summit Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of rare diseases. The company employs a research-driven business model, leveraging its proprietary technologies and expertise to identify and develop novel drugs targeting specific genetic mutations associated with these rare diseases. Summit Therapeutics Inc aims to bring its drug candidates through preclinical and clinical development stages and ultimately secure regulatory approval and commercialize them to benefit patients in need.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 5,887.978 mill. $ - mill. $ -116.025 mill. 702 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 5,887.978 mill.


$ - mill.


$ -116.025 mill.

Employees Shares Outstanding P/E

70


702 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



ELYM

$8.81

$6.0100 214.64%
2024 Year to Date


ELYM

$8.81

$6.0100 214.64%



Eliem Therapeutics Inc

Eliem Therapeutics Inc stock improved 214.64% 2024 year to date.


Eliem Therapeutics Inc*s business model revolves around developing and commercializing innovative therapeutic solutions for various medical conditions.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 238.496 mill. $ - mill. $ -39.240 mill. 27 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 238.496 mill.


$ - mill.


$ -39.240 mill.

Employees Shares Outstanding P/E

-


27 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



BYSI

$2.64

$1.7840 208.41%
2024 Year to Date


BYSI

$2.64

$1.7840 208.41%



Beyondspring Inc

Beyondspring Inc stock improved 208.41% 2024 year to date.


Beyondspring Inc*s business model is focused on the development of innovative cancer therapies, specifically in the areas of immuno-oncology and targeted therapies.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 103.206 mill. $ 1.351 mill. $ -36.280 mill. 39 mill. - Y/Y 0.00 %
Market Cap. Revenues TTM Net Income TTM

$ 103.206 mill.


$ 1.351 mill.


$ -36.280 mill.

Employees Shares Outstanding P/E

-


39 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 0.00 %


MRQ Y/Y - %



DRRX

$1.65

$1.0950 197.30%
2024 Year to Date


DRRX

$1.65

$1.0950 197.30%



Durect Corp

Durect Corp stock went up 197.30% 2024 year to date.


Durect Corp operates as a specialty pharmaceutical company that develops and commercializes innovative products for the treatment of chronic diseases. Their business model revolves around the research, development, and commercialization of their proprietary drug delivery technologies and therapeutics to address unmet medical needs.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 45.393 mill. $ 9.194 mill. $ -36.652 mill. 28 mill. - Y/Y -85.44 %
Market Cap. Revenues TTM Net Income TTM

$ 45.393 mill.


$ 9.194 mill.


$ -36.652 mill.

Employees Shares Outstanding P/E

-


28 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -85.44 %


MRQ Y/Y - %



LSDI

$0.7751

$0.5101 192.49%
2024 Year to Date


LSDI

$0.7751

$0.5101 192.49%



Lucy Scientific Discovery Inc

Lucy Scientific Discovery Inc stock increased 192.49% 2024 year to date.


Lucy Scientific Discovery Inc*s business model revolves around scientific discoveries and innovations.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 13.678 mill. $ 0.010 mill. $ -3.684 mill. 18 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 13.678 mill.


$ 0.010 mill.


$ -3.684 mill.

Employees Shares Outstanding P/E

-


18 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



VKTX

$52.02

$33.7400 184.57%
2024 Year to Date


VKTX

$52.02

$33.7400 184.57%



Viking Therapeutics Inc

Viking Therapeutics Inc shares improved 184.57% 2024 year to date.


Viking Therapeutics Inc is a biopharmaceutical company focused on the development of innovative therapies for metabolic and endocrine disorders.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 5,193.989 mill. $ - mill. $ -80.849 mill. 100 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 5,193.989 mill.


$ - mill.


$ -80.849 mill.

Employees Shares Outstanding P/E

11


100 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



STOK

$16.25

$10.3900 177.30%
2024 Year to Date


STOK

$16.25

$10.3900 177.30%



Stoke Therapeutics Inc

Stoke Therapeutics Inc stock improved 177.30% 2024 year to date.


Stoke Therapeutics Inc operates on a therapeutic platform that utilizes antisense oligonucleotides to target genetic diseases. The company focuses on developing treatments for severe genetic epilepsies, genetic conditions related to a haploinsufficiency gene, and other genetic disorders that lack effective therapies. Their business model centers around identifying and developing novel therapies that modulate gene expression to address the underlying cause of these diseases.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 719.323 mill. $ 9.248 mill. $ -103.396 mill. 44 mill. - Y/Y 13.87 %
Market Cap. Revenues TTM Net Income TTM

$ 719.323 mill.


$ 9.248 mill.


$ -103.396 mill.

Employees Shares Outstanding P/E

-


44 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 13.87 %


MRQ Y/Y - %



TNXP

$1.15

$0.7321 175.19%
2024 Year to Date


TNXP

$1.15

$0.7321 175.19%



Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals Holding Corp stock increased 175.19% 2024 year to date.


Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing and commercializing innovative therapies for psychiatric and neurological conditions. Their business model revolves around identifying potential drug candidates, conducting preclinical and clinical trials to evaluate their efficacy and safety, and ultimately obtaining regulatory approval for their products to bring them to market. Through strategic partnerships and collaborations, they aim to commercialize and distribute their therapies to provide much-needed treatment options for patients.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 93.011 mill. $ 10.250 mill. $ -102.616 mill. 81 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 93.011 mill.


$ 10.250 mill.


$ -102.616 mill.

Employees Shares Outstanding P/E

-


81 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



MNPR

$0.94

$0.5700 154.05%
2024 Year to Date


MNPR

$0.94

$0.5700 154.05%



Monopar Therapeutics Inc

Monopar Therapeutics Inc stock went up 154.05% 2024 year to date.


Monopar Therapeutics Inc operates under a business model focused on developing and commercializing innovative therapeutics for the treatment of various cancers. The company aims to leverage strategic partnerships with academic institutions and other pharmaceutical companies to facilitate the development and distribution of their products.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 15.021 mill. $ - mill. $ -7.609 mill. 16 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 15.021 mill.


$ - mill.


$ -7.609 mill.

Employees Shares Outstanding P/E

-


16 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



DYN

$33.07

$20.0100 153.22%
2024 Year to Date


DYN

$33.07

$20.0100 153.22%



Dyne Therapeutics Inc

Dyne Therapeutics Inc shares increased 153.22% 2024 year to date.


Dyne Therapeutics Inc is a biotechnology company that focuses on developing targeted therapies for patients with serious muscle diseases. They utilize their proprietary technology platform to deliver oligonucleotide therapeutics directly to muscle tissue, aiming to restore muscle function and improve overall patient outcomes.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 2,011.257 mill. $ - mill. $ -208.126 mill. 61 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 2,011.257 mill.


$ - mill.


$ -208.126 mill.

Employees Shares Outstanding P/E

1,679


61 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



ARQT

$8.63

$5.2000 151.60%
2024 Year to Date


ARQT

$8.63

$5.2000 151.60%



Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics Inc shares went up 151.60% 2024 year to date.


Arcutis Biotherapeutics Inc*s business model revolves around developing and commercializing innovative treatments for various dermatological conditions.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 958.349 mill. $ 106.394 mill. $ 76.663 mill. 111 mill. - Y/Y 1,682.42 %
Market Cap. Revenues TTM Net Income TTM

$ 958.349 mill.


$ 106.394 mill.


$ 76.663 mill.

Employees Shares Outstanding P/E

68


111 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 1,682.42 %


MRQ Y/Y - %



PEPG

$17.25

$10.1600 143.30%
2024 Year to Date


PEPG

$17.25

$10.1600 143.30%



Pepgen Inc

Pepgen Inc stock improved 143.30% 2024 year to date.


Pepgen Inc is a biotechnology company that operates on a business model focused on developing and commercializing transformative therapies for genetic diseases. They leverage their expertise in synthetic biology and gene editing technologies to create novel peptide-based therapies that can address previously untreatable genetic conditions. Pepgen Inc aims to partner with healthcare organizations and pharmaceutical companies to bring their innovative treatments to market.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 410.385 mill. $ - mill. $ -74.067 mill. 24 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 410.385 mill.


$ - mill.


$ -74.067 mill.

Employees Shares Outstanding P/E

-


24 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



LEXX

$3.09

$1.8000 139.53%
2024 Year to Date


LEXX

$3.09

$1.8000 139.53%



Lexaria Bioscience Corp

Lexaria Bioscience Corp shares went up 139.53% 2024 year to date.


Lexaria Bioscience Corp is a biotechnology company that focuses on enhancing the bioavailability and effectiveness of certain active compounds through its patented DehydraTECH technology. The company licenses its technology to third-party partners or collaborates with them to develop products in various sectors such as pharmaceuticals, nutraceuticals, and consumer packaged goods. Lexaria generates revenue through licensing fees, royalties from its partners, and potential product sales through its subsidiary, Lexaria Nicotine LLC.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 33.264 mill. $ -3.044 mill. $ -7.240 mill. 11 mill. - Y/Y 314.11 %
Market Cap. Revenues TTM Net Income TTM

$ 33.264 mill.


$ -3.044 mill.


$ -7.240 mill.

Employees Shares Outstanding P/E

-


11 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 314.11 %


MRQ Y/Y - %



EBS

$6.17

$3.5800 138.22%
2024 Year to Date


EBS

$6.17

$3.5800 138.22%



Emergent Biosolutions Inc

Emergent Biosolutions Inc shares increased 138.22% 2024 year to date.


Emergent Biosolutions Inc*s business model focuses on developing and manufacturing specialty products for the prevention and treatment of public health threats.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 322.074 mill. $ 1,184.600 mill. $ -568.500 mill. 52 mill. - Y/Y 81.95 %
Market Cap. Revenues TTM Net Income TTM

$ 322.074 mill.


$ 1,184.600 mill.


$ -568.500 mill.

Employees Shares Outstanding P/E

2,100


52 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 81.95 %


MRQ Y/Y - %



CRVO

$19.01

$11.0100 137.63%
2024 Year to Date


CRVO

$19.01

$11.0100 137.63%



Cervomed Inc

Cervomed Inc stock improved 137.63% 2024 year to date.


Cervomed Inc*s business model focuses on developing and commercializing medical devices to address neurological disorders. They aim to provide innovative solutions to improve the quality of life for patients suffering from conditions like chronic pain and epilepsy. Through their research and development efforts, Cervomed Inc aims to bring technologically advanced products to market, catering to the needs of healthcare professionals and patients worldwide.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 117.301 mill. $ 16.637 mill. $ -0.653 mill. 6 mill. - Y/Y -98.58 %
Market Cap. Revenues TTM Net Income TTM

$ 117.301 mill.


$ 16.637 mill.


$ -0.653 mill.

Employees Shares Outstanding P/E

-


6 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -98.58 %


MRQ Y/Y - %



VERA

$36.02

$20.4100 130.75%
2024 Year to Date


VERA

$36.02

$20.4100 130.75%



Vera Therapeutics Inc

Vera Therapeutics Inc stock improved 130.75% 2024 year to date.


Vera Therapeutics Inc is a pharmaceutical company that specializes in developing and commercializing innovative therapies for patients with rare and serious diseases. Their business model focuses on researching and developing novel drug candidates, conducting clinical trials, and obtaining regulatory approvals to bring their products to market. By targeting niche patient populations with unmet medical needs, they aim to provide effective treatment options and improve patient outcomes.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 1,597.970 mill. $ - mill. $ -102.774 mill. 44 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 1,597.970 mill.


$ - mill.


$ -102.774 mill.

Employees Shares Outstanding P/E

-


44 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



OCEA

$1.41

$0.7939 128.86%
2024 Year to Date


OCEA

$1.41

$0.7939 128.86%



Ocean Biomedical Inc

Ocean Biomedical Inc stock went up 128.86% 2024 year to date.





Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 37.513 mill. $ - mill. $ -97.200 mill. 27 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 37.513 mill.


$ - mill.


$ -97.200 mill.

Employees Shares Outstanding P/E

-


27 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



GERN

$4.87

$2.7300 127.57%
2024 Year to Date


GERN

$4.87

$2.7300 127.57%



Geron Corp

Geron Corp shares increased 127.57% 2024 year to date.


Geron Corp is a biopharmaceutical company that focuses on the discovery and development of therapeutic products for the treatment of cancer and chronic degenerative diseases. Their business model is based on researching and identifying innovative drug candidates, conducting preclinical and clinical trials to evaluate their safety and efficacy, and ultimately partnering with larger pharmaceutical companies for late-stage clinical development and commercialization. Geron Corp aims to leverage their scientific expertise and strategic collaborations to bring novel therapies to market and improve patient outcomes.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 2,822.205 mill. $ 0.317 mill. $ -174.789 mill. 580 mill. - Y/Y -44.78 %
Market Cap. Revenues TTM Net Income TTM

$ 2,822.205 mill.


$ 0.317 mill.


$ -174.789 mill.

Employees Shares Outstanding P/E

25


580 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -44.78 %


MRQ Y/Y - %



DNTH

$26

$14.5500 127.07%
2024 Year to Date


DNTH

$26

$14.5500 127.07%



Dianthus Therapeutics Inc

Dianthus Therapeutics Inc shares improved 127.07% 2024 year to date.


Dianthus Therapeutics Inc is a biotechnology company that focuses on developing novel genetic medicines for patients suffering from rare genetic diseases. Their business model revolves around leveraging cutting-edge gene therapy technologies to design and deliver innovative treatments. By partnering with academic institutions and utilizing a proprietary gene therapy platform, they aim to address unmet medical needs and provide potential new therapies for patients with genetic disorders.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 101.579 mill. $ 0.924 mill. $ -67.395 mill. 4 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 101.579 mill.


$ 0.924 mill.


$ -67.395 mill.

Employees Shares Outstanding P/E

-


4 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



GHRS

$11.99

$6.6400 124.11%
2024 Year to Date


GHRS

$11.99

$6.6400 124.11%



Gh Research Plc

Gh Research Plc shares went up 124.11% 2024 year to date.


Gh Research Plc*s business model revolves around conducting research and development activities in various sectors, likely focused on a specific industry or area of expertise. They may generate revenue through partnerships, collaborations, licensing, or selling their research findings, products, or services to organizations within their targeted market.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 627.483 mill. $ - mill. $ -35.587 mill. 52 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 627.483 mill.


$ - mill.


$ -35.587 mill.

Employees Shares Outstanding P/E

-


52 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



BNTC

$7.31

$4.0381 123.42%
2024 Year to Date


BNTC

$7.31

$4.0381 123.42%



Benitec Biopharma Inc

Benitec Biopharma Inc stock improved 123.42% 2024 year to date.


Benitec Biopharma Inc is a biotechnology company that focuses on developing and commercializing gene therapy products. They utilize their proprietary RNA interference technology to target and silence disease-causing genes, ultimately aiming to provide effective treatment options for various genetic diseases.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 19.125 mill. $ - mill. $ -21.692 mill. 3 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 19.125 mill.


$ - mill.


$ -21.692 mill.

Employees Shares Outstanding P/E

-


3 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



CPHI

$0.2579

$0.1412 120.99%
2024 Year to Date


CPHI

$0.2579

$0.1412 120.99%



China Pharma Holdings Inc

China Pharma Holdings Inc stock increased 120.99% 2024 year to date.


China Pharma Holdings Inc*s business model revolves around the research, development, manufacturing, and marketing of pharmaceutical products.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 3.387 mill. $ 6.231 mill. $ -2.802 mill. 13 mill. - Y/Y -53.10 %
Market Cap. Revenues TTM Net Income TTM

$ 3.387 mill.


$ 6.231 mill.


$ -2.802 mill.

Employees Shares Outstanding P/E

-


13 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -53.10 %


MRQ Y/Y - %



INSM

$63.92

$33.9800 113.49%
2024 Year to Date


INSM

$63.92

$33.9800 113.49%



Insmed Inc

Insmed Inc stock improved 113.49% 2024 year to date.


Insmed Inc operates as a biopharmaceutical company focused on developing novel therapies for serious and rare diseases. The company*s business model revolves around discovering, developing, and commercializing innovative therapies to address significant unmet medical needs. Insmed Inc*s efforts primarily center around leveraging its expertise in biologics and advanced drug delivery technologies to improve the lives of patients with rare pulmonary diseases.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 9,489.308 mill. $ 319.709 mill. $ -746.894 mill. 148 mill. - Y/Y 22.27 %
Market Cap. Revenues TTM Net Income TTM

$ 9,489.308 mill.


$ 319.709 mill.


$ -746.894 mill.

Employees Shares Outstanding P/E

400


148 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 22.27 %


MRQ Y/Y - %



CMMB

$1.13

$0.5922 110.12%
2024 Year to Date


CMMB

$1.13

$0.5922 110.12%



Chemomab Therapeutics Ltd

Chemomab Therapeutics Ltd stock increased 110.12% 2024 year to date.


Chemomab Therapeutics Ltd is a biotechnology company focused on developing innovative treatments for fibrosis-related diseases. Their business model revolves around the research and development of therapeutic antibodies targeting specific pathways involved in fibrosis. By leveraging their scientific expertise and strategic collaborations, the company aims to ultimately bring effective and safe therapies to market, addressing the unmet medical needs of patients suffering from fibrosis.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 265.549 mill. $ - mill. $ 24.221 mill. 235 mill. 10.97 Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 265.549 mill.


$ - mill.


$ 24.221 mill.

Employees Shares Outstanding P/E

9


235 mill.


10.97

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y 192.81 %



XTLB

$2.04

$1.0626 108.72%
2024 Year to Date


XTLB

$2.04

$1.0626 108.72%



Xtl Biopharmaceuticals Ltd

Xtl Biopharmaceuticals Ltd stock increased 108.72% 2024 year to date.


Xtl Biopharmaceuticals Ltd*s business model revolves around developing and commercializing innovative biopharmaceutical products.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 1,111.609 mill. $ - mill. $ 0.000 mill. 545 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 1,111.609 mill.


$ - mill.


$ 0.000 mill.

Employees Shares Outstanding P/E

-


545 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



APM

$4.52

$2.3300 106.39%
2024 Year to Date


APM

$4.52

$2.3300 106.39%



Aptorum Group Limited

Aptorum Group Limited shares went up 106.39% 2024 year to date.


Aptorum Group Limited*s business model revolves around the development, commercialization, and sale of therapeutics and pharmaceutical products for various diseases and health conditions.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 20.436 mill. $ 0.431 mill. $ -4.341 mill. 5 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 20.436 mill.


$ 0.431 mill.


$ -4.341 mill.

Employees Shares Outstanding P/E

31


5 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



TRVI

$2.65

$1.3500 103.85%
2024 Year to Date


TRVI

$2.65

$1.3500 103.85%



Trevi Therapeutics Inc

Trevi Therapeutics Inc shares went up 103.85% 2024 year to date.


Trevi Therapeutics Inc is a biopharmaceutical company that specializes in developing therapies for neurologically mediated conditions. Their business model focuses on identifying and developing innovative treatment options that target specific receptors in the nervous system. By leveraging their expertise in neuroscience and drug development, Trevi aims to bring novel therapies to market and improve the lives of patients suffering from these conditions.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 263.213 mill. $ - mill. $ -26.749 mill. 99 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 263.213 mill.


$ - mill.


$ -26.749 mill.

Employees Shares Outstanding P/E

30


99 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



MRUS

$56.55

$27.9300 97.59%
2024 Year to Date


MRUS

$56.55

$27.9300 97.59%



Merus N v

Merus N V stock increased 97.59% 2024 year to date.


Merus N V is a biotechnology company that operates using a differentiated and competitive business model. Their approach involves strategically targeting and developing bispecific antibodies to treat various types of cancer, leveraging their proprietary technologies and expertise in the field. By focusing on innovative research, efficient drug discovery, and partnerships, they aim to improve patient outcomes and drive growth in the oncology market.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 3,046.335 mill. $ 45.674 mill. $ -176.758 mill. 54 mill. - Y/Y 67.65 %
Market Cap. Revenues TTM Net Income TTM

$ 3,046.335 mill.


$ 45.674 mill.


$ -176.758 mill.

Employees Shares Outstanding P/E

-


54 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 67.65 %


MRQ Y/Y - %



NKTR

$1.17

$0.5752 96.70%
2024 Year to Date


NKTR

$1.17

$0.5752 96.70%



Nektar Therapeutics

Nektar Therapeutics shares improved 96.70% 2024 year to date.


Nektar Therapeutics operates under a business model focused on developing and commercializing innovative medicines. The company*s approach involves utilizing its proprietary technology platforms to create novel therapeutic candidates and establish partnerships with pharmaceutical and biotechnology firms for clinical development and commercialization. Nektar Therapeutics aims to bring transformative therapies to market that address significant unmet medical needs.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 222.775 mill. $ 88.260 mill. $ -293.665 mill. 190 mill. - Y/Y 2.20 %
Market Cap. Revenues TTM Net Income TTM

$ 222.775 mill.


$ 88.260 mill.


$ -293.665 mill.

Employees Shares Outstanding P/E

725


190 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 2.20 %


MRQ Y/Y - %




 1 Day   Week  Current Month of June  30 Days 
Current Quarter Q2 of 2024  90 Days    Ytd    12 Months 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com